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Abstract To characterize the cq-adrenoceptor subtypes, we 
developed a flow cytometry method using the fluorescent ligand 
BODIPY-FL prazosin and the anti-peptide antibody against the 
¢Xlb-adrenoceptor amino terminus (designated IB-N1-C) as 
probes. Three txl-adrenoceptors (tXta, 0rib and tXld) expressed in 
CHO cells were detected by BODIPY-FL prazosin; however, 
only Cttb-adrenoceptor subtype was detected by the anti-peptide 
antibody 1B-NI-C. Furthermore, the flow cytometry analysis 
with 1B-N1-C specifically identified cqb-adrenoceptor in native 
cells of hamster DDT1-MF2 cells, rat hepatocytes andl 
cardiomyocytes. 
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1. Introduction 
cq-adrenoceptors play critical roles in the regulation of a 
variety of physiological processes, such as smooth muscle con- 
traction, myocardial inotropy and chronotropy, and hepatic 
glucose metabolism. Recently, it was found that cq-adreno- 
ceptors comprise a heterogeneous family. Heterogeneity of cq- 
adrenoceptors ({3~lA and O~IB ) was first suggested by pharma- 
cological studies based on differential affinity of a variety of 
agents and differential sensitivity to the alkylating agent CEC, 
and differing requirements for extracellular calcium in signal 
transduction [1-5]. The cloning of three distinct cDNA encod- 
ing cq-adrenoceptor subtypes (c¢1~, Cqb, Cqd) has been re- 
ported [6-11]. The uncertain relationship between the cloned 
and native subtypes has been the source of much confusion; 
however, more recent studies provide evidence supporting the 
idea that the cxl~-adrenoceptor cDNA encodes the pharmaco- 
logical CqA-adrenoceptor subtype whereas the Cqb-adrenocep- 
tor cDNA clone appears to encode the natively expressed, 
pharmacologically defined alB-adrenoceptor subtype [12,13]. 
However, the functional role of the native alD-adrenoceptor 
still remains to be defined, and the CqD-adrenoceptor p otein 
has not been identified yet. 
Since neither Cxl-adrenoceptor subtype-selective ligand nor 
specific antibody is currently available, detection of each re- 
ceptor transcript has been performed to characterize the tissue 
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Throughout this paper, we will use the standardized nomenclature 
system for cq-adrenoceptor subtypes recently recommended by the 
IUPHAR Committee on the Classification of Adrenoceptors. In this 
system, the cloned subtypes are designated in lower case letters as tXla, 
Cqb, and cqd which correspond to the clones previously defined as Ctlc, 
Ctlb , and cqa (or Ctla/a and cqa), respectively. The corresponding 
pharmacological subtypes are designated with upper case letters and 
are defined as tXlg, CqB, and crib, respectively. 
distribution of each o~ 1-adrenOceptOr expression; thus, the dis- 
tribution of cq-adrenoceptor subtypes has been extensively 
characterized in rat, rabbit and human tissues by using North- 
ern blot, in situ hybridization, RNase protection assay and 
RT-PCR techniques [6,7,9,10,14]. It is, however, suggested 
that the level of mRNA expression in a given tissue may 
not directly correlate with the level of receptor protein [15]. 
Ultimately, therefore, studies on both mRNA and receptor 
protein concentrations are required to understand the func- 
tional roles of adrenoceptors and mechanisms of how they are 
involved in physiology and pathology. Additionally, each na- 
tive organ is composed of mixed cell populations expressing 
either a mixture or a unique population of t~l-adrenoceptor 
subtypes. Thus, it is important o determine the expression 
profile of each receptor subtype protein not only at organ 
level but also at cellular level. 
In this report, we examine whether the flow cytometry 
method with fluorescent probes could identify the cell surface 
cq-adrenoceptor f individual cells. We used the fluorescent 
ligand, BODIPY-FL prazosin, as a nonselective probe, and 
we also developed the anti-peptide antibody against Cqb-adre- 
noceptor amino terminus (designated 1B-N1-C) as a subtype- 
selective probe. The antibody identified the Cqb-adrenoceptor 
by Western blotting and immunoprecipitation. With the flow 
cytometry method, we characterized CHO and COS-7 cells 
that were transfected with each cq-adrenoceptor subtype 
cDNA. Furthermore, flow cytometry analysis with the anti- 
body 1B-N1-C selectively identified Cqb-adrenoceptor in na- 
tive cells of DDT1-MF2, a hamster smooth muscle cell line 
[6], and hepatocytes and cardiomyocytes [1,4,15]. 
2. Materials and methods 
2.1. Generation of anti-peptide ant&era 
Peptides were synthesized corresponding to amino acids 12 27 (Pep- 
tide: IB-N1; (C)SAPAQWGELKDANFTG) of the published ham- 
ster tXab-adrenoceptor sequence [6], with the help of an ABI model 
430A peptide synthesizer (Fig. 1A). Peptide 1B-N1 was conjugated 
through the extra amino-terminal cysteine to the activated carrier pro- 
tein KLH (Boehringer Mannheim GmbH, Germany), according to the 
manufacturer's protocol. Synthesized peptide and conjugated KLH 
were purified by gel filtration on a G-25 column and stored at 
-20°C. The amino acid sequence of the peptide was verified by an 
ABI 477A protein sequencer. The conjugated peptide (500 ktg) was 
emulsified in complete Freund's adjuvant and injected subcutaneously 
into Japanese white rabbits at 4-6 sites on the back. Rabbits were 
boosted with the same amount of the peptide mulsified in incomplete 
Freund's adjuvant and bled 14-21 days after the boost. Sera were 
stored at -20°C until use. Antisera were screened against peptides 
by using cross dot systems (Sebia, Moulineaux, France). On the pre- 
wetted 0.22-ktm pore GVHP membrane (Nihon Millipore, Tokyo, Ja- 
pan), slots were coated for 2 h at room temperature with peptide (0.01- 
10 I.tg/slot), washed three times with TTBS and blocked for 1 h at room 
temperature with 10% skimmed milk in TTBS; antisera were added at 
a dilution of 1/100 to 1/10000 for each slot and were allowed to 
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incubate for at least 12 h on a rotator at 4°C. The slots were washed 
three times with TTBS, and were visualized by ABC system (Vector 
Laboratories, Burlingame, CA) as described by the manufacturer. 
2.2. cDNA construction, cell culture and transfection 
Cell culture and transfection were performed as described pre- 
viously [10,16]. For transient expression, human cq~-adrenoceptor 
[10], hamster alb-adrenoceptor [9]and human Cqa-adrenoceptor [17] 
cDNAs were ligated into the SRa promoter-based mammalian expres- 
sion vector pME18S. The constructs were transfected into COS-7 cells 
by the DEAE-dextran method, and cells were assayed 48 72 h after 
transfection. For stable expression, human ald-adrenoceptor cDNAs 
were ligated into the pSV-neo-R expression vector, which contains the 
neomycin resistance gene for selection of stable transformants. CHO 
cells were transfected with the above plasmids by LipofecTAMIN 
(Gibco/BRL, Life Technologies, Gaithersburg, MD, USA). The cells 
were maintained in F-12 medium (Gibco/BRL, Life Technologies, 
Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum 
and G418 (200 gg/ml). We also used a CHO cell line stably expressing 
alb-adrenoceptor and oha-adrenoceptor as eported previously [11,16]. 
DDT1MF2 cells were maintained in Dulbecco's modified Eagle's me- 
dium containing lucose (4.5 g/l), streptomycin (100 lag/ml), penicillin 
(105 U/l) and supplemented with 10% fetal bovine serum. The medium 
was changed every 3 days, and the confluent cells were subcultured at 
a ratio of 1:10. 
2.3. Membrane preparation and radioligand binding assay 
Membranes of COS-7 and CHO cells were prepared as described 
previously [10,16]. Briefly, the cells were collected and disrupted by 
the sonicator (model SONIFIER 250, setting 5 for 8 s) in ice-cold 
buffer containing 5 mM Tris-HC1 pH 7.4, 1 mM MgC12, 10 mM 
EGTA, 250 mM sucrose, 1 mM PMSF, 1 gg/ml pepstatin A, 1 lag/ 
ml leupeptin, 100 laM benzamidine). The mixture was then centrifuged 
at 3000xg for 10 min. The supernatant fraction was centrifuged at 
35 000 xg  for 20 min. The resulting pellet was resuspended in binding 
buffer (50 mM Tris-HC1 pH 7.4, 12.5 mM MgCI2, 10 mM EGTA, 
1 mM PMSF, 1 gg/ml pepstatin A, 1 lag/ml leupeptin, 100 laM ben- 
zamidine) and stored -80°C until use. Membrane aliquots (10 lag of 
protein) were incubated for 60 min at 25°C with approximately 80 pM 
of [125I]HEAT, an cxl-adrenoceptor antagonist radioligand, 125I-(2-~- 
(4-hydroxy phenyl)-ethylaminomethyl)-tetralone, in a final volume of 
250 lal of binding buffer. After dilution with ice-cold buffer, samples 
were immediately filtered through Whatmann GF/C glass fiber filters 
with a Brandel cell harvester (Model-30, Gaithersburg, MD, USA). 
Specific [12~I]HEAT binding was experimentally determined from the 
difference between counts in the absence and presence of 10 laM 
phentolamine. Ki values were generated by the iterative curve-fitting 
program LIGAND [18]. The protein concentration was measured 
using the BCA protein assay kit (Pierce, Rockford, IL, USA). 
2.4. Photoaffinity labeling 
Photoaffinity labeling was performed by a modification of the pro- 
cedure of Terman et al. [19,20]. Briefly, 10 gg of membrane fraction 
was incubated at 37°C for 1 h in buffer containing 0.3 nM [125I]aryl 
azidoprazosin, then photolyzed for 10 min under a EN160L/J UV 
mineral lamp (Spectronics, Westburg, NY, USA). The membranes 
in the reaction mixture were pelleted by centrifugation, fractionated 
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and 
subjected to a BAS 2000 system (Fuji, Tokyo, Japan) to visualize 
incorporated [12SI]aryl azidoprazosin. 
2.5. Immunoprecipitation 
After photoaffinity labeling, the labeled membrane (10 gg of pro- 
tein) was resuspended in 450 gl of binding buffer, then 50/al of 5% (v/ 
v) Triton X-100 was added, and the mixture was vortexed before 
allowed to solubilize on ice for 1 h. Lysates were centrifuged in a 
microfuge for 30 min at 10000×g two times, to sediment insoluble 
material. 400 gl of the supernatant was subsequently used for immu- 
noprecipitation. Solubilized material was incubated with 4 lal of anti- 
serum for at least 12 h on a rotator at 4°C. Nonspecific immunopre- 
cipitation was assessed either by using nonimmune rabbit serum or by 
using the anti-peptide antiserum plus excess antigenic peptide. After 
1 h incubation with 50 gl of 50% (w/v) protein A-Sepharose CL-4B 
(Pharmacia Biotech, Tokyo, Japan), the resulting complex was col- 
lected by centrifugation (100×g, 30 s) and washed three times in 200 
lal of buffer containing 10 mM Tris-HCl pH 7.4, 150 mM NaC1, 1 mM 
EDTA, 1 mM PMSF, 1 gg/ml pepstatin A, 1 lag/ml eupeptin, 100 laM 
benzamidine. The pellets were solubilized and subjected to sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis. 
2.6. Preparation of primary cells 
Rat isolated hepatocytes were prepared by the collagenase perfusion 
method as described previously [4]. The yield of cells from one liver 
averaged 1.5 × l0 s, with 88-95% viability as estimated by trypan blue 
exclusion. Light microscopic analysis howed that ~ 97% of the cells 
were hepatocytes. 
Rat ventricular myocytes were enzymatically isolated using the 
method of Isenberg and Klockner [21]. Briefly, rats weighing 150- 
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Fig. 1. Probes for flow cytometry. (A) Schematic diagram of the alb-adrenoceptor. Following the generally accepted model of G-protein- 
coupled receptors, the seven highly homologous hydrophobic regions are shown as membrane-spanning domains. The amino acid sequences of 
the 1B-N1 (hamster), and the sequences of the same region for rat and human are also shown. (B) and (C) represent chemical structure of pra- 
zosin and BODIPY-FL prazosin, respectively. 
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Fig. 2. Characterization f antibodies in alb-adrenoceptor-transfected CHO cells. (A) Immunoblot against membrane proteins prepared from 
transfected and non-transfected CHO cells. Each sample (10 or 20 I.tg of protein) was applied on the 7.5% SDS-PAGE, transferred to GHPV 
membrane by Western blotting, and then probed with nonimmune, immune sera, or immune sera with immunogen peptide. CHO membrane 
proteins probed with the anti-peptide antibody (1:250 dilution) (lanes 1, 2), nonimmune antibody (lanes 3, 4) and the antibody with immuno- 
gen peptide (lanes 5, 6). Lanes 1, 3, 5 :10  ~tg of protein from CHO membrane-transfected cqb-adrenoceptor cDNA. Lanes 2, 4, 6 :20 ktg of 
protein from wild-type CHO-K1 membrane. The numbers on the left show the relative positions of the molecular weight markers run simulta- 
neously on the same gel. (B) Photoaffinity labeling with [12SI]aryl azidoprazosin and immunoprecipitation f Cqb-adrenoceptor derived from 
transfected CHO cells. All procedures were performed as described in section 2. Photoaffinity labeling was performed with 300 pM [125I]aryl 
azidoprazosin with (lane 2) or without (lane 1) prazosin. After photoaffinity labeling, membrane pellets were solubilized and immunoprecipi- 
tated. Lanes 3-5 represent the immunoprecipitates of antiserum (lane 3), pre-blocked by its corresponding peptide (lane 4), and pre-immune ser- 
um from the same rabbit (lane 5). 
200 g were anesthetized byether, and the hearts were quickly removed 
and rinsed in calcium-free Tyrode solutions [NaC1 135 mM, KC1 5.4 
mM, NaH2PO4 0.3 mM, HEPES 5.0 mM, MgC12 0.5 mM, glucose 5.6 
mM, pH 7.4]. Using a Langendorff technique, collagenase (Yakult, 
Tokyo) of 50 units/ml was perfused for 10-20 min. Ventricular mus- 
cles were minced by scissors and dispersed with gentle agitation, and 
filtered by a 200 ~tm nylon mesh. Cells were stored in KB medium (L- 
glutamic monopotassium 50 mM, taurine 10 mM, KC1 25 mM, 
KH2PO4 10 mM, EGTA 0.5 mM, HEPES 10 mM, MgCI~ 3 mM, 
glucose 10 mM, pH 7.4). 
2. 7. Flow cytometry analysis 
For the analysis with BODIPY-FL prazosin, CHO and COS-7 cells 
were trypsinized and washed twice with PBS. Cells were incubated for 
30 min at room temperature in 100 I.tl of BODIPY-FL prazosin buffer 
containing 1% BSA, 0.01% Pluoronic F127, 1 ~tM BODIPY-FL pra- 
zosin in PBS. Cells were diluted to 500 I11 with PBS and stored up to 
lh .  
For the analysis by anti-peptide antibodies, cells were trypsinized, 
washed twice with PBS, and fixed in 4% paraformaldehyde/PBS solu- 
tion for 5 min at room temperature then washed with PBS. Ceils were 
incubated for 30 min at 4°C with the primary antiserum (diluted 1/ 
100), washed three times, incubated with FITC-conjugated sheep anti- 
rabbit IgG (Organon Teknika, Durham, NC) or Cy3-conjugated goat 
anti-rabbit IgG (Chemicon International, Temecura, CA) for 60 min 
at 4°C, and again washed three times with PBS. 
Analysis of the cells was performed using a FACScan flow cyt- 
ometer (Becton Dickinson and Co., Mountain View, CA, USA). To 
avoid artifacts arising from autofluorescence of dead cells and cellular 
debris, data acquisition was electrically gated for large particles pre- 
sumably representing intact cells by forward and side scatter. Since 
the wavelengths of excitation and emission of BODIPY-FL prazosin 
are similar to those of fluorescein, we used a flow cytometry standard 
setting adjusted to routine double staining techniques employing 
FITC (FL-1) and Cy3 (FL-2) using the operating program LYSIS- 
II. Routinely, data from green fluorescence of 104 cells were subjected 
to histogram and dot-plot analysis. 
2.8. Materials 
Complete Freund's adjuvant and incomplete Freund's adjuvant 
were purchased from Difco (Detroit, MI). [125I]Aryl azidoprazosin 
and [125I]HEAT (specific activity, 2200 Ci/mmol) were purchased 
from New England Nuclear. Acrylamide and other chemicals used 
for SDS-PAGE were from Bio-Rad (Richmond, CA). Reagents for 
peptide synthesis were from ABI-Japan (Tokyo, Japan); Prazosin HC1 
(Pfizer, Brooklyn, NY), BODIPY-FL prazosin (Molecular Probes, 
Eugene, OR) and phentolamine (Sigma, St. Louis, MO). All other 
reagents were of the highest analytical grade. 
3. Results 
3.1. Transient and stable transformants 
COS-7 cells and CHO-K1 wild-type cells did not contain 
any detectable [125I]HEAT binding sites. By contrast, when 
transfected with the plasmids containing cq-adrenoceptor 
cDNAs (ala, Cqb and cqd-adrenoceptor), the COS-7 cells ex- 
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Fig. 3. Flow cytometry analysis of transfected COS-7 cells. COS-7 cells transiently transfected with hamster ~qb-adrenoceptor (A and B) or ex- 
pression vector pME18S only (C and D) were analyzed by the staining method using BODIPY-FL prazosin (A, B, C and D), with (A and C) 
and without anti-peptide antiserum with Cy3-1abeled secondary antibody (B and D), respectively. The cells circled as 'Positive' are considered 
to be cells expressing hamster Cqb-adrenoceptor (more details are discussed in the text). X-axis, relative fluorescence of BODIPY-FL; Y-axis, re- 
lative fluorescence of Cy3. 
pressed [125I]HEAT binding sites of only one affinity. The 
binding properties are characteristic of each cq-adrenoceptor 
subtype as previously reported [22]. We also examined the 
transfection efficiency by in situ I]-gal assay [23], and 7-10% 
of the COS-7 cells were positively stained (not shown). For 
stable transformants, everal G418 resistant clones for each 
receptor cDNA that express 1000-10000 fmol/mg protein 
binding sites were chosen and used for further studies. The 
Bm~ and Kd for each CHO cell line were 1300 + 120 fmol/mg 
protein, 110 + 17 pM (etla, n = 3), 5500 + 80 fmol/mg protein, 
60+0.57 pM 0Xlb, n = 3) and 1100+ 51 fmol/mg protein, 
300 + 24 pM (~la, n = 6), respectively. 
3.2. Characterization o f  the probes 
Western blotting showed that the antiserum obtained (de- 
signated 1B-N1-C) specifically detected a broad band of ,~ 90 
kDa in membranes from tXlb-transfected CHO cells (Fig. 2A, 
lane 1). On the other hand, however, the same antibody did 
not recognize any specific band in wild-type CHO-KI cells 
(lane 2). The 90 kDa band was not detected by the nonim- 
mune serum (lane 3, 4) or by the antiserum that was co-in- 
cubated with 1 laM of immunogen peptide (lanes 5, 6). 
Photoaffinity labeling experiments showed a broad band 
with molecular weight of 90 kDa detected with [125I]aryl azi- 
doprazosin only in membranes from tXlb-transfected CHO 
cells (Fig. 2B, lane 1), but no band labeled in membranes 
prepared from wild-type CHO-K1 cells (data not shown). 
The broad band was blocked by either the cq-adrenoceptor 
antagonist of prazosin (100 nM) (Fig. 1B, lane 2) or phento- 
lamine (10 ~tM, data not shown), indicating that it represents 
txm-adrenoceptor. This photoaffinity-labeled broad 90 kDa 
band is identical in its molecular size to that detected by 
Western blotting (Fig. 2A). Also, as shown in lane 3 of Fig. 
2B, the antiserum immunoprecipitated the[125I]aryl azidopra- 
zosin-labeled 90 kDa protein in tXlb-transfected CHO cell 
membranes. Pre-treatment with the corresponding antigen 
peptide (10 IxM) inhibited the immunoprecipitation f the 
photoaffinity-labeled protein (Fig. 2B, lane 4). The nonim- 
mune serum could not immunoprecipitate the photoaffinity- 
labeled protein (Fig. 2B, lane 5). Also, an unrelated peptide 
KSGLKTDKSD (corresponding to the cqa-adrenoceptor 
residues 219-228, 10 ktM [10]) was unable to inhibit immuno- 
precipitation of the photoaffinity-labeled tXlb-adrenoceptors in 
the same membrane (data not shown). 
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Utilizing the membrane preparations of cqa, ~lb, Cqd-adre- 
noceptor transformants, we also examined the ligand binding 
affinity of BODIPY-FL prazosin. The radioligand binding 
studies with [12SI]HEAT showed that the Kd of BODIPY-FL 
prazosin is almost the same for all receptor subtypes; thus, 
300 nM for cqa, 300 nM for alb and 350 nM for Cqd, respec- 
tively (n = 2 each). 
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3.3. Flow cytometry analysis 
After transfection with the Cqb-adrenoceptor cDNA, the 
COS-7 cells were double-stained by both BODIPY-FL prazo- 
sin and antibody 1B-N1C (Fig. 3A), or stained only by BOD- 
IPY-FL prazosin (Fig. 3B). When transfected, approximately 
9-12% of COS-7 cells were positively stained with BODIPY- 
FL prazosin (circled as 'Positive' in Fig. 3B), which are also 
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Fig. 4. Flow cytometry analysis of transfected CHO cells. CHO cells transfected with human cqa-adrenoceptor (O~la), hamster cqb-adrenoceptor 
(atb), human ald-adrenoceptor (Cqd) and wild-type CHO-K1 cells (CHO-K1) were analyzed by FACScan flow cytometer. (A) Cells stained by 
1 ~tM BODIPY-FL prazosin with (PZN-FL+PZN) or without (PZN-FL) 1 pM of cold prazosin, and no stain (-).  (B) Cells stained with anti- 
peptide antiserum (Ab+) or nonimmune serum (Ab--) and FITC-labeled secondary antibody. 
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positively double-stained by the antibody 1B-N1C (circled as 
'Positive' in Fig. 3A). Furthermore, the BODIPY-FL prazosin 
staining of these cells was inhibited by 1 I.tM of cold prazosin 
(data not shown), suggesting these cells (circled as 'Positive' in 
Fig. 3A and B) may be the COS-7 cells successfully expressing 
alb-adrenoceptor. When the empty vector pME18s was trans- 
fected, no cell was positively stained by both BODIPY-FL 
prazosin and antibody 1B-N1C (Fig. 3C) or stained only by 
BODIPY-FL prazosin (Fig. 3D). 
To characterize the subtype selectivity of these probes, we 
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Fig. 5. Analysis of DDT1-MF2 and freshly isolated native cells. DDTI-MF2 cell line (A) and freshly isolated hepatocytes (B) and cardiomyo- 
cytes (C) were fixed, stained with anti-peptide antiserum (Ab+) or nonimmune serum (Ab-) and FITC-labeled secondary antibody and ana- 
lyzed by FACScan flow cytometer. 
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further examined CHO cells stably expressing each cq-adre- 
noceptor subtype by either BODIPY-FL prazosin or the anti- 
body 1B-N1C. As shown in Fig. 4, all the cell lines expressing 
al-adrenoceptor subtype were stained by BODIPY-FL prazo- 
sin. This staining was inhibited by prazosin (1 /aM), and no 
signal was detected in the wild-type CHO-K1 cells (Fig. 4 A). 
Interestingly, the intensity of the fluorescence was not equal 
for all the cell lines; thus, the fluorescence intensity of the ah-  
adrenoceptor-expressing cells was weaker compared to the 
Cqb- or ald-adrenoceptor-expressing cells (Fig. 4A). These re- 
sults showed that BODIPY-FL prazosin specifically stained 
the al-adrenoceptor, but in a subtype-nonselective manner. 
In contrast o BODIPY-FL prazosin, the flow cytometry anal- 
ysis with the antibody 1B-N1-C detected only the cqb-adreno- 
ceptor-expressing CHO cells with little staining in the CHO 
cells expressing other receptor subtypes, indicating that the 
antibody 1B-N1C was an Cqb-adrenoceptor-selective probe 
(Fig. 4B). 
With the antibody 1B-N1-C, we further examined the sev- 
eral native cells which were previously shown to express phar- 
macologically defined alB-adrenoceptor [24,25]. As shown in 
Fig. 5, DDT1MF2 cells, hepatocytes and cardiomyocytes were 
specifically stained by the antibody I B-N1-C. 
4. Discussion 
Fluorescence-activated flow cytometry has been widely 
adopted to identify specific antigens on the cell surface. How- 
ever, few fluoroligands or antibodies have been developed and 
successfully used for G-protein coupled receptors [26-28], 
mainly because of the poor quantitation and visualization 
due to their weak signal, high level of tissue autofluorescence, 
and a lack of fluorescent staining specificity. In the present 
study, we showed that BODIPY-FL prazosin can be used as a 
specific fluorescent ligand for aa-adrenoceptor, although the 
Kd value of BODIPY-FL prazosin is approximately 100 times 
larger than that of the original compound prazosin. All the 
cell lines expressing al-adrenoceptor subtypes were stained by 
BODIPY-FL prazosin; however, the fluorescence intensity 
was not the same for all subtypes (Fig. 4). While it is not 
clear why only the cqa-adrenoceptor-expressing cells were 
weakly stained with BODIPY-FL prazosin compared to 
others, potential explanations could involve the different cel- 
lular distribution of the receptor protein; alternatively, the 
proportion of the receptor proteins localized on the cell sur- 
face could be different and smaller for cqa-adrenoceptor c m- 
pared to other receptor subtypes, since the Kd of BODIPY-FL 
prazosin and the density of receptor sites in membrane pre- 
parations monitored by radioligand binding assay were not 
much different among the subtypes. 
The flow cytometry analysis provides us with important 
information, such as the amount of the receptor protein pres- 
ent on the cell surface. Also, the analysis can identify the cells 
expressing the specific receptor protein in a heterogenous 
group of cells. This information is often difficult to obtain 
for ~l-adrenoceptor by conventional radioligand binding as- 
say, since most radioligands used for identifying cq-adreno- 
ceptor are highly lipophilic and easily taken up into the intact 
cells. Thus, it has been difficult to determine whether some 
specialized cells or all the cells in a tissue express cqb-adreno- 
ceptor on the cell surface. With the antiserum 1B-N1-C that 
can specifically detect he extracellular N-terminus peptide of 
147 
0hb-adrenoceptor, ur flow cytometry analysis could show 
that most of the isolated hepatocytes and myocytes express 
cqb-adrenoceptors n the cell surface. This is the first demon- 
stration that Cqb-adrenoceptor protein can be identified in the 
pharmacologically well-characterized am-adrenoceptor-ex- 
pressing tissues [1,4,6,15]. 
In summary, the flow cytometry analysis with BODIPY-FL 
prazosin can successfully identify cq-adrenoceptors, and with 
the specific probe for the alb-adrenoceptor protein, the anti- 
peptide antibody 1B-N1-C, the flow cytometry analysis can 
selectively identify the Cqb-adrenoceptor protein even in the 
native tissues. Flow cytometry analysis with specific fluoroli- 
gands or subtype-selective antibody would be a sensitive and 
useful method to pharmacologically characterize the cell sur- 
face receptor protein of individual cells. Also, the approach 
would be potentially useful to monitor the cellular regulation 
of the receptor protein, such as receptor internalization. 
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